A Study of E7389 in Advanced/Metastatic Breast Cancer Patients
Public ClinicalTrials.gov record NCT00097721. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Open Label Study of E7389 (Halichondrin B Analog) in Patients With Advanced/Metastatic Breast Cancer Previously Treated With Chemotherapy Including An Anthracycline and A Taxane
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if E7389 is a safe and effective treatment for advanced/metastatic breast cancer.
Study identification
- NCT ID
- NCT00097721
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 104 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2004
- Primary completion
- Oct 31, 2006
- Completion
- Oct 31, 2006
- Last update posted
- Apr 21, 2013
2004 – 2006
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Jonesboro | Arkansas | — | — |
| Not listed | Deer Park | California | — | — |
| Not listed | La Verne | California | — | — |
| Not listed | Pasadena | California | — | — |
| Not listed | Pomona | California | — | — |
| Not listed | Brooksville | Florida | — | — |
| Not listed | New Port Richey | Florida | — | — |
| Not listed | Plantation | Florida | — | — |
| Not listed | New Orleans | Louisiana | — | — |
| Not listed | Southaven | Mississippi | — | — |
| Not listed | Missoula | Montana | — | — |
| Not listed | Syracuse | New York | — | — |
| Not listed | Middletown | Ohio | — | — |
| Not listed | Memphis | Tennessee | — | — |
| Not listed | Amarillo | Texas | — | — |
| Not listed | Richardson | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00097721, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 21, 2013 · Synced Sep 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00097721 live on ClinicalTrials.gov.